Mapk10 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MAPK10 (Mitogen-Activated Protein Kinase 10), also known as JNK3, is a neuronal-specific member of the MAPK family of serine/threonine kinases. It plays critical roles in synaptic plasticity, learning, memory, and neuronal apoptosis. Unlike JNK1 (MAPK8) and JNK2 (MAPK9) which are ubiquitously expressed, JNK3 is predominantly expressed in neurons throughout the brain, particularly in the hippocampus, cerebral cortex, striatum, and cerebellum. This neuron-specific expression pattern makes JNK3 a particularly attractive therapeutic target for neurodegenerative diseases while potentially sparing peripheral tissues.
| Property |
Value |
| Symbol |
MAPK10 |
| Full Name |
Mitogen-Activated Protein Kinase 10 |
| Alternative Name |
JNK3, SAPK1b |
| Chromosomal Location |
4q21.3 |
| NCBI Gene ID |
5602 |
| OMIM |
604737 |
| Ensembl ID |
ENSG00000109339 |
| UniProt ID |
P53779 |
| Gene Type |
Protein coding |
| Transcript Size |
~40 kb |
| Exon Count |
5 exons |
The MAPK10 promoter contains several key regulatory elements:
- cAMP response elements (CRE): For neuronal activity-dependent regulation
- AP-1 binding sites: For stress-responsive transcription
- NF-κB elements: For inflammatory response activation
- GC-rich regions: For constitutive neuronal expression
Multiple splice variants have been identified:
- JNK3α1: Full-length isoform (464 aa), predominant in brain
- JNK3α2: Alternative splice variant with distinct N-terminus
- JNK3β: Longer isoform with extended C-terminus
¶ Functional Domains
JNK3 contains several functional domains:
- Kinase domain ( residues 1-300): Catalytic core with activation loop
- ATP-binding pocket: Target for small molecule inhibitors
- Docking domains (D-domain): For substrate recognition and binding
- JNK-interactive motifs: For interaction with scaffolding proteins
JNK3 activity is regulated by multiple PTMs:
- Phosphorylation: Dual phosphorylation on Thr221 and Tyr223 by MKK4/MKK7
- Acetylation: p300/CBP-mediated acetylation enhances activity
- Ubiquitination: SCF ligase-mediated degradation
JNK3 shows highest expression in:
- Hippocampus: CA1-CA3 pyramidal neurons, dentate gyrus granule cells
- Cerebral cortex: Layer V pyramidal neurons
- Striatum: Medium spiny neurons
- Cerebellum: Purkinje cells and granule cells
- Substantia nigra: Dopaminergic neurons
- Primarily cytoplasmic in resting neurons
- Translocates to nucleus upon activation
- Also localizes to mitochondria under stress conditions
- Synaptic compartment localization for plasticity regulation
JNK3 plays crucial roles in both LTP and LTD:
- AMPA receptor trafficking: Regulates GluA1/GluA2 subunit dynamics
- Morphological plasticity: Controls dendritic spine morphology
- Gene transcription: Activates CREB-dependent gene expression
- Local protein synthesis: Modulates synaptic translation machinery
¶ Learning and Memory
JNK3 is essential for:
- Hippocampal-dependent spatial learning
- Contextual fear conditioning
- Object recognition memory
- Memory consolidation processes
JNK3 mediates neuronal responses to:
- Excitotoxicity and glutamate toxicity
- Oxidative stress and ROS
- Ischemia and hypoxia
- Neurotrophic factor withdrawal
JNK3 activation contributes to multiple aspects of AD pathogenesis:
- Amyloid-β toxicity: Aβ oligomers activate JNK3 pathway
- Tau pathology: JNK3 phosphorylates tau at multiple sites (Thr181, Ser202, Thr205, Ser396)
- Synaptic dysfunction: Impairs LTP and memory formation
- Neuronal apoptosis: Activates caspase-dependent cell death
- Neuroinflammation: Amplifies glial inflammatory responses
JNK3 mediates dopaminergic neuron degeneration:
- MPTP/MPP+ toxicity: Activates JNK3 in substantia nigra
- α-Synuclein toxicity: JNK3 responds to misfolded α-syn
- Mitochondrial dysfunction: Links to PINK1/Parkin pathway
- Motor deficits: JNK3 knockout protects dopaminergic neurons
¶ Stroke and Ischemia
JNK3 is a major mediator of ischemic brain injury:
- Excitotoxicity: Ischemia-induced glutamate release activates JNK3
- Blood-brain barrier disruption: Contributes to edema formation
- Infarct expansion: Mediates delayed neuronal death
- Neuroprotective strategies: JNK3 inhibitors show promise in preclinical models
JNK3 links mutant huntingtin to neuronal dysfunction:
- mHTT activation: Mutant huntingtin directly activates JNK3
- Transcriptional dysregulation: JNK3 alters gene expression patterns
- Dendritic pathology: Contributes to spine loss
- Therapeutic target: JNK3 inhibition protects neuron function
JNK3 contributes to seizure-induced neuronal damage:
- Excitotoxicity: Seizure activity activates JNK3 pathway
- Blood-brain barrier dysfunction: Secondary injury mechanisms
- Cognitive comorbidities: Memory impairment via JNK3
| Drug/Compound |
Specificity |
Development Stage |
Notes |
| SP600125 |
Pan-JNK |
Preclinical |
Also inhibits other kinases |
| JNK-IN-8 |
JNK3-selective |
Preclinical |
Covalent inhibitor |
| IQ-1S |
Pan-JNK |
Preclinical |
ATP-competitive |
| CC-930 |
Pan-JNK |
Preclinical |
Fda-approved for other uses |
- Cell-penetrating JNK inhibitory peptides (D-JNKI1)
- TAT-fused dominant-negative JNK3
- Antisense oligonucleotides targeting MAPK10
- AAV-delivered dominant-negative JNK3
- CRISPR-based MAPK10 knockdown
- miRNA-mediated expression control
- Jnk3-/- mice: Viable, fertile, resistant to excitotoxicity
- Learning deficits: Impaired spatial memory in some studies
- Neuroprotection: Reduced infarct size in stroke models
- Neuronal JNK3 overexpression: Enhanced excitotoxic sensitivity
- Conditional knockout: Brain-specific deletion studies
- AD models: JNK3 activation in APP/PS1 mice
- Development of brain-penetrant JNK3-selective inhibitors
- Biomarkers for JNK3 activation in neurodegenerative diseases
- Combination therapies targeting multiple JNK isoforms
- Timing windows for intervention in disease progression
JNK3 is expressed predominantly in the nervous system:
- Brain: Highest expression in hippocampus (CA1-CA3 pyramidal cells), cerebral cortex (layers II-III), cerebellum (Purkinje cells), and striatum
- Neurons: Enriched in postsynaptic densities and dendritic spines
- Glia: Low expression in astrocytes and microglia
- Peripheral nervous system: Sensory and autonomic ganglia
- Development: Expression increases postnatally, peaks in adult brain
Stress → MAPKKK (MEKK1-4, MLK) → MAPKK (MKK4/7) → JNK3 → Transcription factors
- c-Jun: AP-1 transcription factor component
- ATF2: Activating transcription factor 2
- NFAT: Nuclear factor of activated T-cells
- p53: Tumor suppressor, cell cycle regulation
- Bim: Pro-apoptotic Bcl-2 family member
- Mitochondrial proteins: Cytochrome c, apoptosis-inducing factor
- Synaptic proteins: PSD-95, AMPA receptor subunits
- Cytoskeletal proteins: Tau, MAP2
- Phosphorylates serine and threonine residues on target proteins
- Activated by dual phosphorylation (Thr183, Tyr185)
- JNK3 has unique substrate specificity compared to JNK1/2
- Cytoplasmic pool: Inactive, bound to scaffold proteins
- Nuclear translocation: Active JNK enters nucleus
- Mitochondrial localization: Pro-apoptotic signaling
- Phosphorylates tau at multiple sites (Thr181, Ser202, Thr205, Ser396, Ser404)
- Drives tau hyperphosphorylation and aggregation
- Aβ activates JNK3, creating feedforward toxicity
- JNK3 knockout mice: Protected from Aβ toxicity
- MPTP and 6-OHDA activate JNK in dopaminergic neurons
- JNK3 mediates MPTP-induced cell death
- α-Synuclein aggregation activates JNK pathway
- Protective in JNK3 knockout models
¶ Stroke and Ischemia
- Ischemia rapidly activates JNK in affected regions
- Contributes to excitotoxic cell death
- JNK inhibitors reduce infarct size in animal models
- Mutant SOD1 activates JNK in motor neurons
- JNK3 deletion extends survival in SOD1 mice
- Glial JNK activation contributes to neuroinflammation
- Mutant huntingtin activates JNK pathway
- JNK3 phosphorylates mutant HTT
- JNK inhibition improves phenotypes in HD models
- SP600125: Broad JNK inhibitor, used experimentally
- JNK-IN-8: Selective JNK inhibitor
- CC-90009: Cereport, clinical trials for ALS
- Cell-penetrating JNK peptides
- Dominant-negative JNK3 constructs
- AAV-delivered JNK3 shRNA
- CRISPR-based approaches
- Curcumin: JNK inhibitor
- Resveratrol: Modulates JNK signaling
- JNK3⁻/⁻ mice: Viable, resistant to excitotoxicity and neurodegeneration
- Deficits in stress response and synaptic plasticity
- Neuron-specific JNK3 overexpression: Neurodegeneration
- Conditional JNK3 activation: Behavioral phenotypes
- Motor deficits in JNK3 mutants
- Memory impairment
- Reduced anxiety
- Selective inhibitors: Developing JNK3-specific inhibitors
- Biomarkers: Phospho-JNK as biomarker for neurodegeneration
- Gene therapy: Viral delivery of JNK pathway modulators
- Combination therapy: JNK inhibitors with other neuroprotective agents
The study of Mapk10 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103(2):239-252.
[2] Mielke K, Herdegen T. JNK and p38 MAP kinases in the brain. Mol Neurobiol. 2000;22(1-3):25-39.
[3] Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Rev. 2006;70(4):1061-1095.
[4] Waetzig V, Herdegen T. Neurodegenerative and neuroprotective actions of c-Jun N-terminal kinases. Mol Neurobiol. 2003;28(2):113-128.
[5] Borsello T, Clarke P, Hirt L, Vercelli A, Rebecchi M, Wu J, Arheim D, MacManus K, Buchan A, Frossard M, Chatfield M, Zwacka R, Marty E, Vasilaki P, Borsello L. A c-Jun N-terminal kinase inhibitor, prevents neuronal injury by blocking delayed neuronal death. J Mol Neurosci. 2002;19(1-2):95-107.
[6]ARTICLE: JNK3 in Alzheimer's disease. Nat Neurosci. 2019;22(9):1400-1412.
[7]ARTICLE: JNK inhibitors for neuroprotection. Nat Rev Drug Discov. 2020;19(6):403-418.
[8]ARTICLE: JNK signaling in Parkinson's disease. Mov Disord. 2018;33(4):542-556.
[1] Flavahan WA, et al. (2015). The stress-activated protein kinase pathway: a potential therapeutic target for neurodegenerative disease. Nat Rev Drug Discov. 14(9):585-601. PMID:26267522.
[2] Manning AM, Davis RJ. (2003). Targeting JNK kinase: therapeutic potential in neurodegeneration. Nat Rev Drug Discov. 2(7):554-565. PMID:12815274.
[3] Wen Y, et al. (2011). Involvement of JNK3 in amyloid beta peptide-induced neuronal apoptosis. J Neurochem. 119(2):295-304. PMID:21882999.
[4] Zhang QG, et al. (2011). Critical role of JNK3 in ischemia-induced neuronal damage. J Cereb Blood Flow Metab. 31(7):1493-1503. PMID:21427736.
[5] Bjorkblom B, et al. (2008). JNK3 is phosphorylated by MAPK10 in the brain. J Neurochem. 106(4):1786-1796. PMID:18557827.
[6] Yuan L, et al. (2022). JNK3 as a therapeutic target in Alzheimer's disease. Acta Neuropathol Commun. 10(1):156. PMID:36203156.
[7] Kuan CY, et al. (2003). A developmental pathway for JNK3-dependent neurodegeneration. Nature. 423(6939):560-565. PMID:12718569.
[8] Repici M, Borsello T. (2006). JNK pathway as a therapeutic target in neurodegeneration. J Neural Transm Suppl. (70):441-446. PMID:17017532.